A股異動丨露笑科技(002617.SZ)封漲停 擬增發投資碳化硅晶材料
格隆匯2月21日丨露笑科技(002617.SZ)開盤即漲停,不就即現回落,現又再度封板。報6.6元,成交量放大至9.85億元,最新總市值99.7億元。露笑科技昨日公告,公司近期正在籌劃非公開發行股票事項,募集資金主要用於投資碳化硅晶體材料和製備項目。本次非公開發行的股票數量按照募集資金總額除以發行價格確定,且不超過本次發行前總股的30%,即4.53億股,最終發行數量以中國證監會核准的發行數量為準。此前,露笑科技2020年第一季度預計淨利8100萬元至1億元,同比增長0.57%-24%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.